FTY720 Inhibits Proliferation and Epithelial-mesenchymal Transition in Cholangiocarcinoma by Inactivating STAT3 Signaling

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2014 Oct 27

PMID 25344679

Citations 29

Authors

Zhaoyang Lu

Jiabei Wang

Tongsen Zheng

Yingjian Liang

Dalong Yin

Ruipeng Song

Tiemin Pei

Shangha Pan

Hongchi Jiang

Lianxin Liu

Affiliations

Soon will be listed here.

Abstract

Background: Interleukin 6 (IL-6)-mediated signal transducers and activators of transcription 3 (STAT-3) phosphorylation (activation) is aberrantly sustained in cholangiocarcinoma cells resulting in enhanced myeloid cell leukemia 1 (Mcl-1) expression and resistance to apoptosis. FTY720, a new immunosuppressant, derived from ISP-1, has been studied for its putative anti-cancer properties. This study aimed to elucidate the mechanism by which FTY720 mediates antitumor effects in cholangiocarcinoma (CC) cells.

Methods: Three CC cell lines were examined, QBC939, TFK-1, and HuCCT1. The therapeutic effects of FTY720 were evaluated in vitro and in vivo. Cell proliferation, apoptosis, cell cycle, invasive potential, and epithelial- mesenchy-mal transition (EMT) were examined.

Results: FTY720 greatly inhibited CC cells proliferation and EMT in vitro and in vivo, and this effect was associated with dephosphorylation of STAT3tyr705. FTY720 induced apoptosis and G1 phase arrest in CC cells, and inhibited invasion of CC cells. Western blot analysis showed that FTY720 induced cleavage of caspases 3, 8 and 9, and of PARP, in a dose-dependent manner, consistent with a substantial decrease in p-STAT3, Bcl-xL, Bcl-2, survivin, cyclin D1, cyclin E, N-cadherin, vimentin, VEGF and TWIST1. In vivo studies showed that tumor growth and metastasis were significantly suppressed after FTY720 treatment.

Conclusions: These results suggest that FTY720 induces a significant decrease in p-STAT3, which inhibits proliferation and EMT of CC cells, and then induces G1 phase arrest and apoptosis. We have characterized a novel immunosuppressant, which shows potential anti-tumor effects on CC via p-STAT3 inhibition. FTY720 merits further investigation and warrants clinical evaluation.

Citing Articles

Cholangiocarcinoma Malignant Traits Are Promoted by Schwann Cells through TGFβ Signaling in a Model of Perineural Invasion.

de Franchis V, Petrungaro S, Pizzichini E, Camerini S, Casella M, Somma F Cells. 2024; 13(5.

PMID: 38474330 PMC: 10930666. DOI: 10.3390/cells13050366.

Role of the PP2A Pathway in Cholangiocarcinoma: State of the Art and Future Perspectives.

Cristobal I, Lamarca A Cancers (Basel). 2022; 14(21).

PMID: 36358840 PMC: 9657793. DOI: 10.3390/cancers14215422.

Targeting Epithelial-to-Mesenchymal Transition in Radioresistance: Crosslinked Mechanisms and Strategies.

Qiao L, Chen Y, Liang N, Xie J, Deng G, Chen F Front Oncol. 2022; 12:775238.

PMID: 35251963 PMC: 8888452. DOI: 10.3389/fonc.2022.775238.

Targeting May Result in Enhanced Migration of Cancer Cells in Bladder Carcinoma.

Chen C, Meng E, Wu S, Lai H, Lu Y, Yang M Cancers (Basel). 2021; 13(17).

PMID: 34503284 PMC: 8431630. DOI: 10.3390/cancers13174474.

Targeting the Sphingosine Kinase/Sphingosine-1-Phosphate Signaling Axis in Drug Discovery for Cancer Therapy.

Gupta P, Taiyab A, Hussain A, Alajmi M, Islam A, Hassan M Cancers (Basel). 2021; 13(8).

PMID: 33920887 PMC: 8071327. DOI: 10.3390/cancers13081898.

References

Chua C, Lee D, Ling M, Zhou C, Man K, Ho J . FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Int J Cancer. 2005; 117(6):1039-48. DOI: 10.1002/ijc.21243. View

Azuma H, Takahara S, Ichimaru N, Wang J, Itoh Y, Otsuki Y . Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res. 2002; 62(5):1410-9. View

Rath K, Naidu S, Lata P, Bid H, Rivera B, McCann G . HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer. Cancer Res. 2014; 74(8):2316-27. PMC: 4286190. DOI: 10.1158/0008-5472.CAN-13-2433. View

Tedesco-Silva H, Mourad G, Kahan B, Boira J, Weimar W, Mulgaonkar S . FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation. 2004; 77(12):1826-33. View

Landowski T, Oshiro M, Turkson J, Levitzki A, Savino R, Ciliberto G . Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999; 10(1):105-15. DOI: 10.1016/s1074-7613(00)80011-4. View

Gu L, Talati P, Vogiatzi P, Romero-Weaver A, Abdulghani J, Liao Z . Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. Mol Cancer Ther. 2014; 13(5):1246-58. PMC: 4013199. DOI: 10.1158/1535-7163.MCT-13-0605. View

Khan S, Thomas H, Davidson B, Taylor-Robinson S . Cholangiocarcinoma. Lancet. 2005; 366(9493):1303-14. DOI: 10.1016/S0140-6736(05)67530-7. View

Heinrich P, Behrmann I, Haan S, Hermanns H, Muller-Newen G, Schaper F . Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003; 374(Pt 1):1-20. PMC: 1223585. DOI: 10.1042/BJ20030407. View

Cheng F, Wang H, Cuenca A, Huang M, Ghansah T, Brayer J . A critical role for Stat3 signaling in immune tolerance. Immunity. 2003; 19(3):425-36. DOI: 10.1016/s1074-7613(03)00232-2. View

10.

Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D . FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood. 2007; 111(1):275-84. PMC: 2200813. DOI: 10.1182/blood-2006-10-053884. View

11.

Azuma H, Takahara S, Horie S, Muto S, Otsuki Y, Katsuoka Y . Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J Urol. 2003; 169(6):2372-7. DOI: 10.1097/01.ju.0000064938.32318.91. View

12.

Li C, Shao Y, Ng K, Liu X, Ling C, Ma Y . FTY720 suppresses liver tumor metastasis by reducing the population of circulating endothelial progenitor cells. PLoS One. 2012; 7(2):e32380. PMC: 3288101. DOI: 10.1371/journal.pone.0032380. View

13.

Levy D, Lee C . What does Stat3 do?. J Clin Invest. 2002; 109(9):1143-8. PMC: 150972. DOI: 10.1172/JCI15650. View

14.

Kasprzycka M, Marzec M, Liu X, Zhang Q, Wasik M . Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc Natl Acad Sci U S A. 2006; 103(26):9964-9. PMC: 1502562. DOI: 10.1073/pnas.0603507103. View

15.

Isomoto H, Kobayashi S, Werneburg N, Bronk S, Guicciardi M, Frank D . Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology. 2005; 42(6):1329-38. DOI: 10.1002/hep.20966. View

16.

Graler M, Goetzl E . The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J. 2004; 18(3):551-3. DOI: 10.1096/fj.03-0910fje. View

17.

Tannapfel A, Benicke M, Katalinic A, Uhlmann D, Kockerling F, Hauss J . Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut. 2000; 47(5):721-7. PMC: 1728101. DOI: 10.1136/gut.47.5.721. View

18.

Liao A, Broeg K, Fox T, Tan S, Watters R, Shah M . Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. Blood. 2011; 118(10):2793-800. PMC: 3172796. DOI: 10.1182/blood-2011-01-331447. View

19.

Gao J, Richardson D . The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression. Blood. 2001; 98(3):842-50. DOI: 10.1182/blood.v98.3.842. View

20.

Okada K, Shimizu Y, Nambu S, Higuchi K, Watanabe A . Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol. 1994; 9(5):462-7. DOI: 10.1111/j.1440-1746.1994.tb01275.x. View